Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway - Episode 8

Best Practices in Managing Patients on Capivasertib

November 4, 2024

Joyce O’Shaughnessy, MD, Laura Huppert, MD, Heather Moore, Pharm D

Panelists discuss the key advice they would offer to fellow physicians, nurse practitioners, advanced practice providers, and pharmacists involved in the care of patients on capivasertib, emphasizing best practices for patient management and communication.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer

EP. 2: First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer

EP. 3: Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer

EP. 4: Overview of the CAPItello-291 Trial

EP. 5: Clinical Experience with Capivasertib

EP. 6: Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy

EP. 7: Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia

Now Viewing

EP. 8: Best Practices in Managing Patients on Capivasertib

Video content above is prompted by the following:

All faculty: What advice would you give to fellow physicians, nurse practitioners, advanced practice providers, pharmacists, and other care providers who are involved in the care of patients on capivasertib?